J
Jeffrey L. Lennox
Researcher at Emory University
Publications - 95
Citations - 7717
Jeffrey L. Lennox is an academic researcher from Emory University. The author has contributed to research in topics: Viral load & Raltegravir. The author has an hindex of 42, co-authored 94 publications receiving 7236 citations. Previous affiliations of Jeffrey L. Lennox include Grady Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV-Positive and HIV-Negative Individuals in VACS (Veterans Aging Cohort Study)
Vincent C. Marconi,Vincent C. Marconi,Meredith S. Duncan,Kaku So-Armah,Vincent Lo Re,Joseph K. Lim,Adeel A. Butt,Adeel A. Butt,Matthew Bidwell Goetz,Matthew Bidwell Goetz,Maria C. Rodriguez-Barradas,Charles Alcorn,Charles Alcorn,Jeffrey L. Lennox,Joshua A. Beckman,Amy C. Justice,Amy C. Justice,Matthew S. Freiberg +17 more
TL;DR: VACS participants (regardless of HIV status) with elevated bilirubin levels had a lower risk of incident total CVD, acute myocardial infarction, heart failure, and ischemic stroke events after adjusting for known risk factors.
Journal ArticleDOI
Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults.
Daniel R. Feikin,Cheryl M. Elie,Matthew Bidwell Goetz,Jeffrey L. Lennox,George M. Carlone,Sandra Romero-Steiner,Patricia F. Holder,William A. O'Brien,Cynthia G. Whitney,Jay C. Butler,Robert F. Breiman +10 more
TL;DR: Findings confirm that absorption with a heterologous pneumococcal polysaccharide (e.g., 22F) is necessary to remove nonspecific antibodies in a standardized IgG ELISA forneumococcal capsular antibodies in HIV-infected adults.
Journal ArticleDOI
Global HIV/AIDS Medicine
TL;DR: Any person hoping to learn about progressive multifocal leukoencephalopathy, biliary tract diseases, outcomes of surgery, or manifestations ofThrombotic thrombocytopenic purpura in HIV-infected patients will be disappointed.
Journal ArticleDOI
A Single Dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-Induced Bone Loss in Treatment-naïve HIV-infected Patients: a Phase IIb Trial
Ighovwerha Ofotokun,Kehmia Titanji,Cecile D. Lahiri,Aswani Vunnava,Antonina Foster,Sara E. Sanford,Anandi N. Sheth,Jeffrey L. Lennox,Andrea Knezevic,Laura Ward,Kirk A. Easley,Philip Powers,M. Neale Weitzmann,M. Neale Weitzmann +13 more
TL;DR: A single dose of ZOL administered at ART initiation prevented ART- induced bone loss through the first 48 weeks of ART, the period when ART-induced bone loss is most pronounced.
Journal ArticleDOI
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
TL;DR: A more robust immune restoration was observed among HBV/HCV coinfected subjects who developed liver enzyme elevation after antiretroviral initiation compared with other groups, which suggests that ARV-related liver enzymes elevation may be related in part to immune reconstitution, as measured by changes in CD4 T-cell counts.